Long-Term Safety of Patients with Parkinson's Disease Receiving rAAV2-Neurturin (CERE-120) Gene Transfer

Human Gene Therapy

Volumn 27, Issue 7, 2016, Pages 522-527

  Marks, William J ^a   Baumann, Tiffany L ^b   Bartus, Raymond T ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ISIS PHARMACEUTICALS   (United States)

^c RTBioconsultants Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEURTURIN; RECOMBINANT ADENO ASSOCIATED VIRUS SEROTYPE 2 VECTOR; UNCLASSIFIED DRUG; NRTN PROTEIN, HUMAN;

ADVERSE OUTCOME; ARTICLE; CONTROLLED STUDY; DIZZINESS; DRUG SAFETY; DYSKINESIA; EYE DISEASE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INJURY; INSOMNIA; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MENTAL DISEASE; METABOLIC DISORDER; MOOD CHANGE; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PARKINSON DISEASE; PATIENT SAFETY; PHYSICAL EXAMINATION; PSYCHOSIS; PUTAMEN; RESPIRATORY TRACT DISEASE; SKIN DISEASE; STEREOTAXIC SURGERY; SUBSTANTIA NIGRA; URINARY TRACT DISEASE; VASCULAR DISEASE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ADMINISTRATION AND DOSAGE; BRAIN; CLINICAL TRIAL; DEPENDOPARVOVIRUS; FEMALE; GENE THERAPY; GENE VECTOR; GENETICS; MALE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SAFETY;

BRAIN; DEPENDOVIRUS; FEMALE; GENETIC THERAPY; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEURTURIN; PARKINSON DISEASE; PUTAMEN; SAFETY;

EID: 84987600814     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2015.134     Document Type: Article

References (19)

1. Kotzbauer PT, Lampe PA, Heuckeroth RO, et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467-470.
2. Horger BA, Nishimura MC, Armanini MP, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 1998;18:4929-4937.
3. Gasmi M, Herzog CD, Brandon EP, et al. Striatal deliveryof neurturinbyCERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther 2007;15:62-68.
4. Herzog CD, Dass B, Holden JE, et al. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopa-minergic nigrostriatal system in aged monkeys. Mov Disord 2007;22:1124-1132.
5. Gasmi M, Brandon EP, Herzog CD, et al. AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: Long-term efficacy and tol-erability of CERE-120 for Parkinson's disease. Neurobiol Dis 2007;27:67-76.
6. Kordower JH, Herzog CD, Dass B, et al. Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 2006;60: 706-715.
7. Marks WJ Jr., Ostrem JL, Verhagen L, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: An open-label, Phase I trial. Lancet Neurol 2008;7:400-408.
8. Marks WJ, Bartus RT, Siffert J, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: A double-blind, randomised, controlled trial. Lancet Neurol 2010;9:1164-1172.
9. Bartus RT, Baumann TL, Siffert J, et al. Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. Neurology 2013;80:1-4.
10. Olanow CW, Bartus RT, Baumann TL, et al. Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol 2015;78: 248-257.
11. Bartus RT, Kordower JH, Johnson EM Jr., et al. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a synucleinopathies. Neurobiol Dis 2015;78:162-171.
12. Bartus RT, Kordower JH, Johnson EM Jr., et al. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a synucleinopathies. Neurobiol Dis 2015;78:162-171.
13. Bartus RT, Weinbert MS, Samulski RJ. Parkinson's disease gene therapy: Success by design meets failure by efficacy. Mol Ther 2014;22:487-497.
14. Bartus RT, Brown L, Wilson A, et al. Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: Support for nigral targeting in Parkinson's disease. Neurobiol Dis 2011;44:38-52.
15. Manfredsson FP, et al. Tight long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 2009;17:1857-1867.
16. Manfredsson FP, et al. Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther 2009;17:980-991.
17. Su X, Bankiewicz KS. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic ni-grostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009;20:1627-1640.
18. Herzog CD, Brown L, Kruegel BR, et al. Enhanced neurotrophic distribution, cell signaling and neu-roprotection following substantia nigral versus striatal delivery of AAV2-NRTN (CERE-120). Neu-robiol Dis 2013;58C:38-48.
19. Bartus RT, Herzog CD, Chu Y, et al. Bioactivity of AAV2-neurturin gene therapy (CERE-120): Differences between Parkinson's disease and nonhu-man primate brains. Mov Disord 2011;26:27-36.